Medpace Holdings Inc
SWB:01P
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
M
|
Medpace Holdings Inc
SWB:01P
|
US |
|
K
|
KDDI Corp
DUS:DIP
|
JP |
|
M
|
Medpace Holdings Inc
F:01P
|
US |
Intrinsic Value
The intrinsic value of 
Medpace Holdings Inc (01P) under the Base Case is 454.77 EUR per share.
Compared with the current market price of 580 EUR, the stock appears
Overvalued by 22% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Medpace Does
Medpace Holdings is a contract research company that helps drug and medical device makers run clinical trials. It designs study plans, manages sites and patients, collects trial data, and handles the regulatory and operational work needed to test new treatments. Its customers are mainly biopharma companies, biotech startups, and medical device firms that need outside expertise to get products through development.
- Headquarters
- United States of America US
- Employees
- 6 300
- IPO date
- Aug 11, 2016
Medpace Holdings has a narrow economic moat
Changing providers during an active clinical trial can require transferring study records, shifting site coordination and onboarding a new team, creating time and reliability risks for the sponsor. This gives Medpace some protection on studies already underway, though sponsors can still move work to other CROs or internal teams.
Read the full moat analysis
Revenue & Expenses Breakdown
Medpace Holdings Inc
Earnings Waterfall
Medpace Holdings Inc
The intrinsic value for Medpace Holdings Inc (01P) under the Base Case is 454.77 EUR.
Compared with the current market price of 580 EUR, the stock appears Overvalued by 22% .
